Pancreatic Cancer Research

ResearcherDokkyo Medical UniversityActive in the last 2 years

Keiichi Kubota

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4484-7708; OpenAlex author ID A5100669296. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 6 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 11

  1. Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS. Last author DOI 10.3390/cancers16050910↗
  2. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00280-021-04267-5↗
  3. A proposal to modify the 8th edition of the UICC staging system for pancreatic adenocarcinoma. Co-author DOI 10.1007/s00423-021-02167-z↗
  4. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001826↗
  5. Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective. Co-author DOI 10.1186/s12957-021-02192-8↗
  6. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/anticanres.14925↗
  7. Clinical Predictors of Unresectable Disease at Laparotomy in Patients With Pancreatic Ductal Adenocarcinoma Planning to Undergo Surgical Resection. Last author DOI 10.21873/anticanres.15335↗
  8. Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-020-01900-0↗
  9. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/invivo.11700↗
  10. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection. First author DOI 10.1002/bjs.9775↗
  11. Recent advances and limitations of surgical treatment for pancreatic cancer. Co-author DOI 10.5306/wjco.v2.i5.225↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taku Aoki · 6 shared papers, 2019–2024 · strength 0.96
  2. Shozo Mori · 6 shared papers, 2019–2024 · strength 0.96
  3. Takayuki Shimizu · 6 shared papers, 2015–2021 · strength 0.67
  4. Takatsugu Matsumoto · 5 shared papers, 2021 · strength 0.65
  5. Y. Kurata · 2 shared papers, 2020–2021 · strength 0.31
  6. Yasuo Imai · 2 shared papers, 2020–2021 · strength 0.31
  7. Tsengelmaa Jamiyan · 1 shared paper, 2020 · strength 0.13
  8. Jun Iwata · 1 shared paper, 2021 · strength 0.13
  9. Takehiro Okabayashi · 1 shared paper, 2021 · strength 0.13
  10. Tatsuo Iiyama · 1 shared paper, 2021 · strength 0.13
  11. Yasuhiro Shimada · 1 shared paper, 2021 · strength 0.13
  12. Kenta Sui · 1 shared paper, 2021 · strength 0.13
  13. Takashi Suzuki · 1 shared paper, 2019 · strength 0.09
  14. Masato Katoh · 1 shared paper, 2015 · strength 0.07
  15. Mitsugi Shimoda · 1 shared paper, 2015 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.